920 results about "High doses" patented technology

The present invention provides pharmaceutical compositions for controlled release of pharmaceutically active agents, especially those with a high water solubility, high dose, and/or short half-life. In addition, the present application provides methods for preparing and using such pharmaceutical compositions.

The present invention provides methods of using cord blood and cord blood-derived stem cells in high doses to treat various conditions, diseases and disorders. The high-dose cord blood and cord blood-derived stem cells have a multitude of uses and applications, including but not limited to, therapeutic uses for transplantation and treatment and prevention of disease, and diagnostic and research uses. In particular, the cord blood or cord blood-derived stem cells are delivered in high doses, e.g., at least 3 billion nucleated cells per treatment, where treatment may comprise a single or multiple infusions. The invention also provides for the use of cord blood or cord blood-derived stem cells from multiple donors without the need for HLA typing.

A photo resist composition contains a polymer resin, a first photo acid generator (PAG) requiring a first dose of actinic energy to generate a first photo acid, and a photo base generator (PBG) requiring a second dose of actinic energy, different from the first dose, to generate a photo base. The amounts and types of components in the photo resist are selected to produce a hybrid resist image. Either the first photo acid or photo base acts as a catalyst for a chemical transformation in the resist to induce a solubility change. The other compound is formulated in material type and loading in the resist such that it acts as a quenching agent. The catalyst is formed at low doses to induce the solubility change and the quenching agent is formed at higher doses to counterbalance the presence of the catalyst. Accordingly, the same frequency doubling effect of conventional hybrid resist compositions may be obtained, however, either a line or a space may be formed at the edge of an aerial image. Feature size may also be influenced by incorporating a quenching agent into the resist composition that does not require photo generation.

A method and system is disclosed which is capable of delivering at a high dose rate, respirable solid aerosols derived from aqueous- or nonaqueous-based solutions containing the desired therapeutic agent(s). The method and system comprises the integration of an aerosol generator, an aerosol evaporator, an aerosol concentrator, and an aerosol flow regulator. The aerosol generator generates 10-30 μm droplets, with a narrow size distribution. The aerosol jet is arrested by a coaxial counter-flow heated air jet, and evaporated rapidly by annular swirling heated air. Most of the air, together with the unwanted solvent vapor, is removed from the aerosol stream during the process of aerosol concentration. The output aerosol carries the dry particles to be inhaled by the patient. The respiratory-governed control of aerosol fluid generation system delivers fluid containing the test agent of interest (drug or toxin) to the aerosol generator throughout inhalation.

The apparatus, method and system for performing a high dose rate brachytherapy procedure in a body cavity may include an at least partially indwelling multi-lumen catheter with a plurality of inflatable balloons coupled thereto. A lumen may be adapted to receive radiation seeds. The balloons, when inflated, may be adapted to administer a substantially uniform radiation isodose to the body cavity. Some embodiments may be well suited to performing intrauterine brachytherapy for the treatment of endometrial carcinoma.

An implantable device for facilitating the healing of voids in bone, cartilage and soft tissue is disclosed. A preferred embodiment includes a cartilage region comprising a polyelectrolytic complex joined with a subchondral bone region. The cartilage region, of this embodiment, enhances the environment for chondrocytes to grow articular cartilage; while the subchondral bone region enhances the environment for cells which migrate into that region's macrostructure and which differentiate into osteoblasts. Another embodiment is arranged for the local delivery of therapeutic agent. A preferred embodiment is a porous resorbable implant, wherein the therapy delivery may be localized in nature, rather than systemic, such that higher doses at the target site may be allowed than would be tolerable by the body systemically.

Metformin Hydrochloride (herein referred to as metformin HCl) that may be 98.5%-100% pure is a high dose drug capable of being directly compressed with specific excipients into tablets having desired, hardness, disintegrating ability, and acceptable dissolution characteristics. Metformin HCl is not inherently compressible and thus presents formulation problems. Excipients used in the formulation enhance the flow and compaction properties of the drug and tableting mix. Optimal flow contributes to uniform die fill and weight control. The binder used ensures sufficient cohesive properties that allow metformin HCl to be compressed using the direct compression method. The tablets produced provide an acceptable in-vitro dissolution profile.

The present invention describes compounds, compositions and methods of using the same comprising lysine covalently attached to amphetamine. These compounds and compositions are useful for reducing or preventing abuse and overdose of amphetamine. These compounds and compositions find particular use in providing an abuse-resistant alternative treatment for certain disorders, such as attention deficit hyperactivity disorder (ADHD), ADD, narcolepsy, and obesity. Oral bioavailability of amphetamine is maintained at therapeutically useful doses. At higher doses bioavailability is substantially reduced, thereby providing a method of reducing oral abuse liability. Further, compounds and compositions of the invention decrease the bioavailability of amphetamine by parenteral routes, such as intravenous or intranasal administration, further limiting their abuse liability.

An enrobed solid form comprising a film enrobing a compacted fill material having at least one active material, the solid form shows a weight loss that is less than 1% during a 30 minutes USP Friability Test, the fill material having a density of at least 0.5 g/ml based on the total solid volume of the solid form and a tensile strength less than 0.9 MPa, and the at least one active material within the solid form has an immediate release profile. The solid form is useful in effective delivery of high dose levels of active material.

The invention describes compounds, compositions and methods of using the same comprising a chemical moiety covalently attached to amphetamine. These compounds and compositions are useful for reducing or preventing abuse and overdose of amphetamine. These compounds and compositions find particular use in providing an abuse-resistant alternative treatment for certain disorders, such as attention deficit hyperactivity disorder (ADHD), ADD, narcolepsy, and obesity. Oral bioavailability of amphetamine is maintained at therapeutically useful doses. At higher doses bioavailability is substantially reduced, thereby providing a method of reducing oral abuse liability. Further, compounds and compositions of the invention decrease the bioavailability of amphetamine by parenteral routes, such as intravenous or intranasal administration, further limiting their abuse liability.

Disclosed herein are methods for treating a vascular leak disorder, hypotension, or a procoagulant state using angiopoietin-2 (Ang-2) antagonist compounds. Also disclosed are methods for treating a vascular leak disorder associated with high dose IL-2 therapy using angiopoietin-2 antagonist compounds. Methods for diagnosing and monitoring vascular leak disorders, hypotension, or a procoagulant state that include the measurement of Ang-2 polypeptide or nucleic acid levels are also disclosed. Methods for inducing a vascular leak using an Ang-2 agonist are also disclosed.

Skin disorders such as, for example, atopic dermatitis, dyshidrosis, eczema, lichen planus, psoriasis, and vitiligo, are treated by applying high doses of ultraviolet light to diseased regions of a patients skin. The dosage employed exceeds 1 MED, an MED being determined for the particular patient being treated, and may range from about 1 MED to about 20 MED or higher. The ultraviolet light has a wavelength within the range of between about 295 nanometers to about 320 nanometers and preferably is between about 300 nanometers and about 310 nanometers. High doses of ultraviolet light are restricted to diseased tissue areas so as to avoid risk of detrimental side affects in healthy skin, which is more susceptible to damage from UV light. Cooling the skin prior to and/or while exposing the skin to the UV light can be used to minimize tissue damage resulting from exposure to the UV light. Higher doses of UV light can therefore be employed without injurious affects.

This invention relates to single session image guided all field simultaneous radiation therapy combined with hyperthermia. Hyperthermia renders the radiation resistant cells as more radiation sensitive cells. The high and super-high dose rate radiation greatly improves the RBE of the photon radiation. It also minimizes photon radiation therapy's OER and cell cycle dependent tumor cell kill by minimizing the repair capacity of cell after photon radiation. Single session hyperthermia and radiation therapy overcomes the thermotolerance-associated inefficiency of hyperthermia treatment as it is when hyperthermia is combined with fractionated, lower dose rate radiation. The synergetic effects of sublethal damage repair inhibiting single session hyperthermia-combined with high dose and dose rate single session radiation therapy, and combined chemotherapy brings the photon radiation therapy's tumor cure and control capabilities closer to high LET radiation therapy.

Plasma is generated using elemental hydrogen, a weak oxidizing agent, and a fluorine containing gas. An inert gas is introduced to the plasma downstream of the plasma source and upstream of a showerhead that directs gas mixture into the reaction chamber where the mixture reacts with the high-dose implant resist. The process removes both the crust and bulk resist layers at a high strip rate, and leaves the work piece surface substantially residue free with low silicon loss.

A method and system for converting low-dose tomosynthesis projection images or reconstructed slices images with noise into higher quality, less noise, higher-dose-like tomosynthesis reconstructed slices, using of a trainable nonlinear regression (TNR) model with a patch-input-pixel-output scheme called a pixel-based TNR (PTNR). An image patch is extracted from an input raw projection views (images) of a breast acquired at a reduced x-ray radiation dose (lower-dose), and pixel values in the patch are entered into the PTNR as input. The output of the PTNR is a single pixel that corresponds to a center pixel of the input image patch. The PTNR is trained with matched pairs of raw projection views (images together with corresponding desired x-ray radiation dose raw projection views (images) (higher-dose). Through the training, the PTNR learns to convert low-dose raw projection images to high-dose-like raw projection images. Once trained, the trained PTNR does not require the higher-dose raw projection images anymore. When a new reduced x-ray radiation dose (low dose) raw projection images is entered, the trained PTNR outputs a pixel value similar to its desired pixel value, in other words, it outputs high-dose-like raw projection images where noise and artifacts due to low radiation dose are substantially reduced, i.e., a higher image quality. Then, from the “high-dose-like” projection views (images), “high-dose-like” 3D tomosynthesis slices are reconstructed by using a tomosynthesis reconstruction algorithm. With the “virtual high-dose” tomosynthesis reconstruction slices, the detectability of lesions and clinically important findings such as masses and microcalcifications can be improved.

Skin disorders such as, for example, atopic dermatitis, dyshidrosis, eczema, lichen planus, psoriasis, and vitiligo, are treated by applying high doses of ultraviolet light to diseased regions of a patients skin. The dosage employed exceeds 1 MED, an MED being determined for the particular patient being treated, and may range from about 1 MED to about 20 MED or higher. The ultraviolet light has a wavelength within the range of between about 295 nanometers to about 320 nanometers and preferably is between about 300 nanometers and about 310 nanometers. High doses of ultraviolet light are preferably restricted to diseased tissue areas so as to avoid risk of detrimental side affects in healthy skin, which is more susceptible to damage from UV light. Cooling the skin prior to and/or while exposing the skin to the UV light can be used to reduce tissue damage resulting from exposure to the UV light. Higher doses of UV light can therefore be employed without injurious affects. A specialized handpiece provides a beam profile especially suitable for application of controlled doses. A specialized delivery device is useful for UV treatment of tissue within the mouth.

Methods of treating MDS, or ameliorating a symptom thereof, are disclosed. Specific methods encompass the administration of one or more vitamin D compounds, or a pharmaceutically acceptable salt, solvate, hydrate, stereoisomer, clathrate, or prodrug thereof, alone or in combination with one or more additional active agents. Other methods include intermittent administration of a high dose of one or more vitamin D compounds, or a pharmaceutically acceptable salt, solvate, hydrate, stereoisomer, clathrate, or prodrug thereof, alone or in combination with one or more additional active agents. Such intermittent administration allows high doses of the vitamin D compounds to be administered while minimizing or eliminating hypercalcemia.

The invention describes compounds, compositions, and methods of using the same comprising a chemical moiety covalently attached to amphetamine. These compounds and compositions are useful for reducing or preventing abuse and overdose of amphetamine. These compounds and compositions find particular use in providing an abuse-resistant alternative treatment for certain disorders, such as attention deficit hyperactivity disorder (ADHD), ADD, narcolepsy, and obesity. Oral bioavailability of amphetamine is maintained at therapeutically useful doses. At higher doses bioavailability is substantially reduced, thereby providing a method of reducing oral abuse liability. Further, compounds and compositions of the invention decrease the bioavailability of amphetamine by parenteral routes, such as intravenous or intranasal administration, further limiting their abuse liability.